{"product_id":"henrui-business-model-canvas","title":"Jiangsu Hengrui Medicine Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHengrui's Blueprint: Business Model Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic engine driving Jiangsu Hengrui Medicine's success with our comprehensive Business Model Canvas. This detailed breakdown illuminates their approach to innovation, market penetration, and sustainable growth in the pharmaceutical sector. Unlock the full blueprint to understand their competitive advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Companies for Co-development and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine actively pursues strategic alliances with major global pharmaceutical corporations. These collaborations focus on co-developing promising drug candidates and out-licensing its innovative pipeline, aiming to expedite global market entry and broaden its revenue base.\u003c\/p\u003e\n\u003cp\u003eA significant illustration of this strategy is the substantial $12 billion potential agreement with GSK. This deal grants GSK global rights to Hengrui's HRS-9821 and eleven other drug programs, underscoring Hengrui's commitment to leveraging external expertise and infrastructure for international expansion.\u003c\/p\u003e\n\u003cp\u003eThese key partnerships allow Hengrui to capitalize on its robust research and development strengths while simultaneously accessing the extensive commercial networks and market reach of established pharmaceutical leaders. This synergy is crucial for transforming its internal innovations into globally recognized treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Academia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine actively partners with top research institutions and academic centers globally, fostering early-stage drug discovery. These collaborations grant access to advanced scientific knowledge and innovative technologies, significantly boosting Hengrui's internal R\u0026amp;D capabilities and pipeline development.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Hengrui announced a significant collaboration with a leading US university focused on novel oncology targets, aiming to accelerate the validation of new therapeutic approaches. This partnership exemplifies Hengrui's strategy to leverage external expertise for scientific rigor and pipeline diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine actively partners with Contract Research Organizations (CROs) to streamline its drug development process. These collaborations are crucial for managing the complex logistics and specialized expertise required for preclinical and clinical trials.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Hengrui's commitment to leveraging CROs was evident in its extensive clinical trial portfolio. For instance, the company was actively involved in numerous global trials, many of which rely heavily on CROs for site management, patient recruitment, and data collection, thereby accelerating the path to market for its innovative therapies.\u003c\/p\u003e\n\u003cp\u003eBy outsourcing these critical functions, Hengrui optimizes its internal resource allocation and gains access to a global network of scientific and regulatory talent. This strategic approach allows the company to conduct a higher volume of trials efficiently, a key factor in its competitive edge within the pharmaceutical industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and AI-driven Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine actively partners with technology firms focused on artificial intelligence and computational drug design. These collaborations are pivotal in boosting Hengrui's capacity for discovering new medicines. For example, their alliance with Iktos utilizes AI-powered molecular design tools to expedite the crucial hit-to-lead and lead optimization phases of drug development.\u003c\/p\u003e\n\u003cp\u003eThis strategic integration of AI ensures a more precise and accelerated pathway for creating novel therapeutic compounds, ultimately making the development process faster, more efficient, and less expensive. Hengrui's commitment to leveraging these advanced technological platforms underscores their dedication to innovation in the pharmaceutical sector.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAI-Powered Drug Discovery:\u003c\/strong\u003e Partnerships with companies like Iktos enhance Hengrui's ability to discover and optimize drug candidates using advanced AI algorithms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccelerated Development Cycles:\u003c\/strong\u003e These collaborations aim to significantly reduce the time and cost associated with bringing new drugs from initial discovery to clinical trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Precision:\u003c\/strong\u003e AI platforms contribute to more accurate identification and refinement of potential drug molecules, improving the likelihood of success.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Focus:\u003c\/strong\u003e Hengrui's strategy involves integrating cutting-edge technology to maintain a competitive edge in the rapidly evolving pharmaceutical landscape.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and Commercialization Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's globalization hinges on strategic alliances with distributors and commercialization partners. These collaborations are essential for penetrating markets beyond China, especially in developing economies and specialized therapeutic sectors. Such partnerships streamline market entry, assist in navigating complex local regulatory landscapes, and bolster product promotion, ultimately ensuring Hengrui’s innovative medicines reach more patients worldwide.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are crucial for Hengrui's international expansion goals. For instance, in 2024, Hengrui continued to expand its global footprint, with a focus on securing distribution agreements in key European and North American markets for its oncology and anesthesia portfolios. The company reported that international sales constituted a growing, albeit still minority, portion of its revenue, highlighting the importance of these external relationships for future growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e Strategic alliances with distributors and commercialization partners are key to extending Hengrui Medicine's market reach beyond China, particularly in emerging markets and specific therapeutic areas.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFacilitating Access:\u003c\/strong\u003e These partners are instrumental in enabling market access, navigating local regulatory requirements, and executing effective product promotion strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobalization Strategy:\u003c\/strong\u003e The successful engagement of these partners is critical for the company's overarching strategy to increase its global presence and make its medicines more widely available to patients internationally.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Partnerships Propel Hengrui's R\u0026amp;D and Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's key partnerships are vital for its global reach and R\u0026amp;D acceleration. Collaborations with major pharmaceutical firms, like the potential $12 billion deal with GSK for global rights to multiple drug programs, highlight Hengrui's strategy to leverage external expertise and infrastructure for international market entry. These alliances are crucial for transforming internal innovations into globally recognized treatments by combining Hengrui's R\u0026amp;D strengths with established commercial networks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eFocus Area\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eExample\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Pharma Corporations\u003c\/td\u003e\n\u003ctd\u003eCo-development, Out-licensing\u003c\/td\u003e\n\u003ctd\u003eExpedite global market entry, broaden revenue\u003c\/td\u003e\n\u003ctd\u003ePotential $12B deal with GSK for HRS-9821 and 11 other programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Institutions\/Academia\u003c\/td\u003e\n\u003ctd\u003eEarly-stage drug discovery\u003c\/td\u003e\n\u003ctd\u003eAccess advanced science, boost R\u0026amp;D capabilities\u003c\/td\u003e\n\u003ctd\u003e2023 collaboration with leading US university on oncology targets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eClinical trial management\u003c\/td\u003e\n\u003ctd\u003eStreamline development, optimize resource allocation\u003c\/td\u003e\n\u003ctd\u003eExtensive 2024 clinical trial portfolio relying on CROs for site management and patient recruitment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Firms (AI)\u003c\/td\u003e\n\u003ctd\u003eAI-powered drug design\u003c\/td\u003e\n\u003ctd\u003eAccelerate discovery and optimization\u003c\/td\u003e\n\u003ctd\u003eAlliance with Iktos for AI-driven molecular design\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\/Commercialization Partners\u003c\/td\u003e\n\u003ctd\u003eMarket penetration (ex-China)\u003c\/td\u003e\n\u003ctd\u003eFacilitate market access, navigate regulations\u003c\/td\u003e\n\u003ctd\u003eExpansion of distribution agreements in key European and North American markets in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's business model focuses on innovative drug R\u0026amp;D and commercialization, targeting unmet medical needs in oncology and other therapeutic areas, leveraging strong clinical trial capabilities and a robust sales network.\u003c\/p\u003e\n\u003cp\u003eThis model emphasizes a vertically integrated approach, from research and development to manufacturing and marketing, aiming to deliver high-value pharmaceutical products to patients and healthcare providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's Business Model Canvas acts as a pain point reliever by providing a clear, one-page snapshot of their complex pharmaceutical operations, enabling rapid understanding and strategic alignment.\u003c\/p\u003e\n\u003cp\u003eThis structured approach simplifies the identification of key value propositions and customer segments, effectively addressing the pain of information overload in a rapidly evolving healthcare market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D) of Innovative Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHengrui's primary focus is the extensive research and development of innovative medicines, particularly in key therapeutic areas like oncology, cardiovascular, metabolic diseases, and immunology. This dedication to scientific advancement is the engine driving their business.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to R\u0026amp;D is substantial, evidenced by their significant investment, which reached 29.40% of revenue in 2024. This financial backing fuels a dynamic pipeline, currently comprising around 400 clinical trials for over 90 promising new drug candidates.\u003c\/p\u003e\n\u003cp\u003eThis robust R\u0026amp;D effort is geared towards discovering novel molecular entities, aiming to provide effective solutions for critical unmet medical needs within the global healthcare landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control of Pharmaceutical Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHengrui Medicine's manufacturing operations are central to its business, focusing on producing high-quality pharmaceuticals. The company adheres to stringent global standards, including EU Good Manufacturing Practice (GMP) and U.S. current Good Manufacturing Practice (cGMP). This commitment ensures that their medicines are consistently safe and effective for patients worldwide.\u003c\/p\u003e\n\u003cp\u003eRigorous quality control is embedded throughout the entire manufacturing process, from raw material sourcing to finished product release. This meticulous approach is crucial for maintaining product integrity, meeting regulatory requirements, and building trust with healthcare providers and patients. In 2023, Hengrui's R\u0026amp;D investment reached 6.61 billion yuan, a significant portion of which supports advanced manufacturing capabilities and quality assurance systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials and Regulatory Affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's core operations revolve around the rigorous execution of clinical trials to validate the safety and effectiveness of its innovative drug candidates. The company actively manages a substantial portfolio of global clinical trials, extending its reach to key markets including the United States, Europe, Australia, Japan, and South Korea. This extensive international presence allows for diverse patient populations and regulatory insights.\u003c\/p\u003e\n\u003cp\u003eSuccessfully navigating intricate regulatory landscapes and obtaining approvals from diverse health authorities worldwide is paramount for Hengrui. This critical activity ensures that their novel therapies can reach patients who need them. In 2024, Hengrui continued to advance its pipeline, with several key drug candidates progressing through various stages of regulatory review across major global markets, underscoring the importance of this function.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing of Approved Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's sales and marketing efforts for its approved medicines are crucial for commercial success. This involves building robust sales networks to engage with healthcare professionals and hospitals, ensuring broad market access for its pharmaceutical products. The company focuses on targeted marketing strategies, particularly for its innovative drug pipeline, which is a significant driver of its revenue.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Hengrui Medicine continued to emphasize the commercialization of its approved drugs, with innovative medicines contributing approximately 50% to its total revenue. This highlights the importance of effective sales and marketing in translating research and development into market share. The company's strategy includes expanding its sales force and implementing data-driven marketing campaigns to reach key stakeholders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Network Expansion:\u003c\/strong\u003e Hengrui Medicine actively builds and maintains a comprehensive sales network reaching hospitals and healthcare providers across China and internationally.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTargeted Marketing Strategies:\u003c\/strong\u003e The company develops specific marketing plans for its diverse portfolio, with a strong focus on educating medical professionals about the benefits of its innovative therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovative Drug Focus:\u003c\/strong\u003e With innovative drugs accounting for nearly 50% of total revenue in 2024, sales and marketing efforts are heavily geared towards promoting these high-value products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommercialization of New Approvals:\u003c\/strong\u003e Post-approval, Hengrui Medicine rapidly deploys sales and marketing teams to ensure swift market penetration and patient access to newly launched medicines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine's intellectual property management is a cornerstone of its business strategy. The company diligently protects its innovative drug candidates through comprehensive patent filings and grants. This proactive approach ensures its research and development investments are safeguarded, maintaining a crucial competitive advantage in the dynamic global pharmaceutical landscape.\u003c\/p\u003e\n\u003cp\u003eHengrui actively pursues patent protection across major markets, including China, Europe, and the United States. As of early 2024, the company had a significant portfolio of patents covering its novel therapies, reflecting substantial R\u0026amp;D expenditure. For instance, in 2023, Hengrui reported R\u0026amp;D expenses of approximately RMB 7.6 billion (around $1.07 billion USD), a portion of which is directly tied to securing and maintaining these intellectual assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Filings:\u003c\/strong\u003e Hengrui consistently files new patent applications for its drug candidates and novel formulations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Protection:\u003c\/strong\u003e Patents are sought in key pharmaceutical markets to ensure broad market exclusivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment Safeguard:\u003c\/strong\u003e IP protection is vital for recouping the significant costs associated with drug discovery and development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Edge:\u003c\/strong\u003e A strong IP portfolio allows Hengrui to differentiate its products and command premium pricing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Innovation: From Discovery to Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHengrui Medicine's key activities encompass robust research and development, stringent manufacturing adhering to global quality standards, and extensive clinical trial management across international markets. The company also focuses on navigating complex regulatory pathways for drug approvals and executing targeted sales and marketing strategies for its innovative therapies.\u003c\/p\u003e\n\u003cp\u003eIntellectual property management, particularly patent protection for its drug candidates, is a critical activity ensuring the safeguarding of R\u0026amp;D investments and maintaining a competitive edge.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eActivity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003eKey Metric\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDiscovery and development of innovative medicines\u003c\/td\u003e\n\u003ctd\u003e29.40% of revenue invested in R\u0026amp;D in 2024; ~400 clinical trials for \u0026gt;90 drug candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eHigh-quality pharmaceutical production\u003c\/td\u003e\n\u003ctd\u003eAdherence to EU GMP and US cGMP standards; 2023 R\u0026amp;D investment of 6.61 billion yuan supported advanced manufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eValidating drug safety and efficacy globally\u003c\/td\u003e\n\u003ctd\u003eTrials conducted in US, Europe, Australia, Japan, South Korea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eObtaining drug approvals from health authorities\u003c\/td\u003e\n\u003ctd\u003eKey drug candidates progressing through regulatory review in major global markets in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales \u0026amp; Marketing\u003c\/td\u003e\n\u003ctd\u003eCommercializing approved medicines\u003c\/td\u003e\n\u003ctd\u003eInnovative drugs contributed ~50% of total revenue in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property Management\u003c\/td\u003e\n\u003ctd\u003eProtecting drug candidates via patents\u003c\/td\u003e\n\u003ctd\u003eSignificant patent portfolio in key markets; 2023 R\u0026amp;D expenses ~RMB 7.6 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Jiangsu Hengrui Medicine Business Model Canvas you are currently previewing is the exact document you will receive upon purchase. This is not a sample or a mockup; it's a direct snapshot of the complete, ready-to-use analysis you'll gain access to. Once your order is confirmed, you'll download this same comprehensive file, allowing you to immediately leverage its insights into Hengrui Medicine's strategic framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611193000313,"sku":"henrui-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/henrui-business-model-canvas.png?v=1754752642","url":"https:\/\/growthsharematrix.com\/products\/henrui-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}